Canada markets closed

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.11+0.10 (+2.00%)
At close: 04:00PM EST
5.11 0.00 (0.00%)
After hours: 04:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.01
Open4.93
Bid4.84 x 1100
Ask5.20 x 800
Day's Range4.84 - 5.22
52 Week Range3.96 - 15.59
Volume114,024
Avg. Volume180,996
Market Cap303.65M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-2.27
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.67
  • Zacks

    Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Zacks

    Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet

    The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • GlobeNewswire

    Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results

    Cash balance of $301.2M expected to fund operations into 2025CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results. “Generation Bio’s mission is to unlock the full promise of genetic medicine by developing novel durable, redosable and titratable DNA therapeutics,” said Geoff McDonough, M.D.,